13F-HR filed by NOVO HOLDINGS A/S
NOVO HOLDINGS A/S filed this 13F-HR for the quarter ended 2017-03-31, filed 2017-05-15, with 22 holding rows worth $939,094,000.
- Accession
- 0000950123-17-005095
- Filer
- CIK 1388325
- Filed
- 2017-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2017
A holdings report, 22 entries on the cover page, a total value of $939,094,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $939,094,000 with VALUE read as thousands by filing date, 13F file number 028-16231. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| INOGEN INC | 45780L104 | COM | 3,549,320 | $275,285,000 | thousands by filing date | |
| ANAPTYSBIO INC | 032724106 | COM | 3,033,504 | $84,180,000 | thousands by filing date | |
| REATA PHARMACEUTICALS INC | 75615P103 | CL A | 3,367,763 | $76,280,000 | thousands by filing date | |
| IRHYTHM HOLDINGS INC COM | 450056106 | Stock | 2,024,448 | $76,119,000 | thousands by filing date | |
| CORVUS PHARMACEUTICALS INC | 221015100 | COM | 3,224,046 | $66,963,000 | thousands by filing date | |
| RA PHARMACEUTICALS INC | 74933V108 | COM | 2,031,562 | $43,252,000 | thousands by filing date | |
| ACCELERON PHARMA INC | 00434H108 | COM | 1,553,937 | $41,133,000 | thousands by filing date | |
| FLEXION THERAPEUTICS INC | 33938J106 | COM | 1,397,718 | $37,613,000 | thousands by filing date | |
| MERUS N V | N5749R100 | COM | 1,410,417 | $34,400,000 | thousands by filing date | |
| SPECTRANETICS CORP | 84760C107 | COM | 1,179,122 | $34,342,000 | thousands by filing date | |
| ObsEva SA | H5861P103 | COM | 3,044,093 | $31,689,000 | thousands by filing date | |
| NABRIVA THERAPEUTICS AG | 62957M104 | SPONSORED ADR | 2,326,544 | $27,919,000 | thousands by filing date | |
| DERMIRA INC | 24983L104 | COM | 748,240 | $25,522,000 | thousands by filing date | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 2,901,927 | $22,664,000 | thousands by filing date | |
| APOLLO ENDOSURGERY INC | 03767D108 | COM | 1,456,972 | $18,241,000 | thousands by filing date | |
| AKEBIA THERAPEUTICS INC | 00972D105 | COMMON STOCK | 1,272,247 | $11,705,000 | thousands by filing date | |
| INVUITY INC | 46187J205 | COM NEW | 1,318,448 | $10,482,000 | thousands by filing date | |
| HTG MOLECULAR DIAGNOSTICS IN | 40434H104 | COM | 1,280,185 | $8,859,000 | thousands by filing date | |
| WRIGHT MED GROUP N V | N96617126 | RIGHT 03/01/2019 | 4,622,032 | $7,072,000 | thousands by filing date | principal |
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 223,317 | $4,862,000 | thousands by filing date | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 127,563 | $510,000 | thousands by filing date | |
| OPKO HEALTH INC | 68375N103 | COM | 259 | $2,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-17-005095 | this filing | 2017-05-15 | acceptance time not in the bulk data set |